Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Chiba (Sapporo, Japan), . Ikeda (Sapporo, Japan), A. Azuma (Tokyo, Japan), Y. Kondoh (Seto, Japan), T. Ogura (Yokohama, Japan), Y. Taguchi (Tenri, Japan), M. Ebina (Sendai, Japan), S. Miyazawa (Osaka, Japan), H. Sakaguchi (Osaka, Japan), M. Suga (Kumamoto, Japan), Y. Sugiyama (Shimotsuke, Japan), T. Nukiwa (Sendai, Japan), S. Kudoh (Tokyo, Japan), H. Takahashi (Sapporo, Japan). Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan. 2249

Member's Comments

No comment yet.

Related content which might interest you: Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 The clinical significance of >5% change in VC in patients with idiopathic pulmonary fibrosis -extended analysis of the pirfenidone trial in Japan Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis (IPF): A comprehensive analysis of outcomes in CAPACITY 2 Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Clinical application of the COPD assessment test (CAT) in patients with idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Late-breaking abstract: Pathological analysis of acute exacerbation of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011